Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Timely renal transplantation for scleroderma end-stage kidney disease patients can improve outcomes and quality of life.

Woodworth TG, Furst DE.

Ann Transl Med. 2019 Feb;7(3):60. doi: 10.21037/atm.2018.12.64. No abstract available.

2.

Identifying Provisional Generic Contextual Factor Domains for Clinical Trials in Rheumatology: Results from an OMERACT Initiative.

Nielsen SM, Tugwell P, de Wit MPT, Boers M, Beaton DE, Woodworth TG, Escorpizo R, Shea B, Toupin-April K, Guillemin F, Strand V, Singh JA, Kloppenburg M, Furst DE, Wells GA, Smolen JS, VeselĂ˝ R, Boonen A, Storgaard H, Voshaar M, March L, Christensen R; Contextual Factors Working Group.

J Rheumatol. 2019 Jan 15. pii: jrheum.181081. doi: 10.3899/jrheum.181081. [Epub ahead of print]

PMID:
30647174
3.

Scleroderma renal crisis and renal involvement in systemic sclerosis.

Woodworth TG, Suliman YA, Li W, Furst DE, Clements P.

Nat Rev Nephrol. 2018 Feb;14(2):137. doi: 10.1038/nrneph.2017.183. Epub 2018 Jan 2.

PMID:
29292373
4.

Content and Construct Validity, Reliability, and Responsiveness of the Rheumatoid Arthritis Flare Questionnaire: OMERACT 2016 Workshop Report.

Bartlett SJ, Barbic SP, Bykerk VP, Choy EH, Alten R, Christensen R, den Broeder A, Fautrel B, Furst DE, Guillemin F, Hewlett S, Leong AL, Lyddiatt A, March L, Montie P, Pohl C, Scholte Voshaar M, Woodworth TG, Bingham CO 3rd.

J Rheumatol. 2017 Oct;44(10):1536-1543. doi: 10.3899/jrheum.161145. Epub 2017 Aug 15.

PMID:
28811351
5.

An OMERACT Initiative Toward Consensus to Identify and Characterize Candidate Contextual Factors: Report from the Contextual Factors Working Group.

Finger ME, Boonen A, Woodworth TG, Escorpizo R, Christensen R, Nielsen SM, Leong AL, Scholte Voshaar M, Flurey CA, Milman N, Verstappen SM, Alten R, Guillemin F, Kloppenburg M, Beaton DE, Tugwell PS, March LM, Furst DE, Pohl C.

J Rheumatol. 2017 Nov;44(11):1734-1739. doi: 10.3899/jrheum.161200. Epub 2017 May 1.

PMID:
28461648
6.

Examining the validity of the rheumatoid arthritis magnetic resonance imaging score according to the OMERACT filter-a systematic literature review.

Woodworth TG, Morgacheva O, Pimienta OL, Troum OM, Ranganath VK, Furst DE.

Rheumatology (Oxford). 2017 Jul 1;56(7):1177-1188. doi: 10.1093/rheumatology/kew445. Review.

7.

How should worsening in osteoarthritis be defined? Development and initial validation of preliminary criteria for clinical worsening in knee and hip osteoarthritis.

Mahler E, den Broeder AA, Woodworth TG, Busch V, van den Hoogen FH, Bijlsma J, van den Ende C.

Scand J Rheumatol. 2017 Sep;46(5):396-406. doi: 10.1080/03009742.2016.1235226. Epub 2017 Feb 7.

PMID:
28276959
8.

Scleroderma renal crisis and renal involvement in systemic sclerosis.

Woodworth TG, Suliman YA, Li W, Furst DE, Clements P.

Nat Rev Nephrol. 2016 Nov;12(11):678-691. doi: 10.1038/nrneph.2016.124. Epub 2016 Sep 19. Review. Erratum in: Nat Rev Nephrol. 2018 Jan 02;:.

PMID:
27641135
9.

Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.

Bijlsma JWJ, Welsing PMJ, Woodworth TG, Middelink LM, Pethö-Schramm A, Bernasconi C, Borm MEA, Wortel CH, Ter Borg EJ, Jahangier ZN, van der Laan WH, Bruyn GAW, Baudoin P, Wijngaarden S, Vos PAJM, Bos R, Starmans MJF, Griep EN, Griep-Wentink JRM, Allaart CF, Heurkens AHM, Teitsma XM, Tekstra J, Marijnissen ACA, Lafeber FPJ, Jacobs JWG.

Lancet. 2016 Jul 23;388(10042):343-355. doi: 10.1016/S0140-6736(16)30363-4. Epub 2016 Jun 7.

PMID:
27287832
10.

Treating to target in established rheumatoid arthritis: Challenges and opportunities in an era of novel targeted therapies and biosimilars.

Woodworth TG, den Broeder AA.

Best Pract Res Clin Rheumatol. 2015 Aug-Dec;29(4-5):543-9. doi: 10.1016/j.berh.2015.10.001. Review.

PMID:
26697765
11.

Preface.

den Broeder AA, Woodworth TG.

Best Pract Res Clin Rheumatol. 2015 Aug-Dec;29(4-5):525-6. doi: 10.1016/j.berh.2015.09.008. Epub 2015 Nov 28. No abstract available.

PMID:
26697763
12.

Feasibility and Domain Validation of Rheumatoid Arthritis (RA) Flare Core Domain Set: Report of the OMERACT 2014 RA Flare Group Plenary.

Bartlett SJ, Bykerk VP, Cooksey R, Choy EH, Alten R, Christensen R, Furst DE, Guillemin F, Halls S, Hewlett S, Leong AL, Lyddiatt A, March L, Montie P, Orbai AM, Pohl C, Voshaar MS, Woodworth TG, Bingham CO 3rd.

J Rheumatol. 2015 Nov;42(11):2185-9. doi: 10.3899/jrheum.141169. Epub 2015 Feb 15. Review.

14.

We still don't know how to taper glucocorticoids in rheumatoid arthritis, and we can do better.

Volkmann ER, Rezai S, Tarp S, Woodworth TG, Furst DE.

J Rheumatol. 2013 Oct;40(10):1646-9. doi: 10.3899/jrheum.130019. No abstract available.

PMID:
24085754
15.

Validation of OMERACT preliminary rheumatoid arthritis flare domains in the NOR-DMARD study.

Lie E, Woodworth TG, Christensen R, Kvien TK, Bykerk V, Furst DE, Bingham CO 3rd, Choy EH; OMERACT RA Flare Working Group.

Ann Rheum Dis. 2014 Oct;73(10):1781-7. doi: 10.1136/annrheumdis-2013-203496. Epub 2013 Jul 12.

PMID:
23852690
16.

Identifying core domains to assess flare in rheumatoid arthritis: an OMERACT international patient and provider combined Delphi consensus.

Bartlett SJ, Hewlett S, Bingham CO 3rd, Woodworth TG, Alten R, Pohl C, Choy EH, Sanderson T, Boonen A, Bykerk V, Leong AL, Strand V, Furst DE, Christensen R; OMERACT RA Flare Working Group.

Ann Rheum Dis. 2012 Nov;71(11):1855-60. doi: 10.1136/annrheumdis-2011-201201. Epub 2012 Jul 6.

PMID:
22772326
17.

Identifying preliminary domains to detect and measure rheumatoid arthritis flares: report of the OMERACT 10 RA Flare Workshop.

Bingham CO 3rd, Alten R, Bartlett SJ, Bykerk VP, Brooks PM, Choy E, Christensen R, Furst DE, Hewlett SE, Leong A, May JE, Montie P, Pohl C, Sanderson TC, Strand V, Woodworth TG; OMERACT RA Flare Definition Working Group.

J Rheumatol. 2011 Aug;38(8):1751-8. doi: 10.3899/jrheum.110401.

PMID:
21807797
18.

Developing a construct to evaluate flares in rheumatoid arthritis: a conceptual report of the OMERACT RA Flare Definition Working Group.

Alten R, Pohl C, Choy EH, Christensen R, Furst DE, Hewlett SE, Leong A, May JE, Sanderson TC, Strand V, Woodworth TG, Bingham CO 3rd; OMERACT RA Flare Definition Working Group.

J Rheumatol. 2011 Aug;38(8):1745-50. doi: 10.3899/jrheum.110400.

PMID:
21807796
19.

Developing a standardized definition for disease "flare" in rheumatoid arthritis (OMERACT 9 Special Interest Group).

Bingham CO 3rd, Pohl C, Woodworth TG, Hewlett SE, May JE, Rahman MU, Witter JP, Furst DE, Strand CV, Boers M, Alten RE.

J Rheumatol. 2009 Oct;36(10):2335-41. doi: 10.3899/jrheum.090369. Epub 2009 Aug 14.

PMID:
19684147
20.

The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis.

Alten R, Gram H, Joosten LA, van den Berg WB, Sieper J, Wassenberg S, Burmester G, van Riel P, Diaz-Lorente M, Bruin GJ, Woodworth TG, Rordorf C, Batard Y, Wright AM, Jung T.

Arthritis Res Ther. 2008;10(3):R67. doi: 10.1186/ar2438. Epub 2008 Jun 5.

21.

Standardized assessment of adverse events in rheumatology clinical trials: summary of the OMERACT 7 drug safety module update.

Lassere MN, Johnson KR, Boers M, Carlton K, Day RO, de Wit M, Edwards IR, Fries JF, Furst DE, Kirwan JR, Tugwell PS, Woodworth TG, Brooks PM.

J Rheumatol. 2005 Oct;32(10):2037-41.

PMID:
16206366
22.

Challenges and progress in adverse event ascertainment and reporting in clinical trials.

Lassere MN, Johnson KR, Woodworth TG, Furst DE, Fries JF, Kirwan JR, Tugwell PS, Day RO, Brooks PM.

J Rheumatol. 2005 Oct;32(10):2030-2. Review.

PMID:
16206364
23.
24.

MRI assessment of knee osteoarthritis: Knee Osteoarthritis Scoring System (KOSS)--inter-observer and intra-observer reproducibility of a compartment-based scoring system.

Kornaat PR, Ceulemans RY, Kroon HM, Riyazi N, Kloppenburg M, Carter WO, Woodworth TG, Bloem JL.

Skeletal Radiol. 2005 Feb;34(2):95-102. Epub 2004 Oct 8.

PMID:
15480649
25.

Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor.

Changelian PS, Flanagan ME, Ball DJ, Kent CR, Magnuson KS, Martin WH, Rizzuti BJ, Sawyer PS, Perry BD, Brissette WH, McCurdy SP, Kudlacz EM, Conklyn MJ, Elliott EA, Koslov ER, Fisher MB, Strelevitz TJ, Yoon K, Whipple DA, Sun J, Munchhof MJ, Doty JL, Casavant JM, Blumenkopf TA, Hines M, Brown MF, Lillie BM, Subramanyam C, Shang-Poa C, Milici AJ, Beckius GE, Moyer JD, Su C, Woodworth TG, Gaweco AS, Beals CR, Littman BH, Fisher DA, Smith JF, Zagouras P, Magna HA, Saltarelli MJ, Johnson KS, Nelms LF, Des Etages SG, Hayes LS, Kawabata TT, Finco-Kent D, Baker DL, Larson M, Si MS, Paniagua R, Higgins J, Holm B, Reitz B, Zhou YJ, Morris RE, O'Shea JJ, Borie DC.

Science. 2003 Oct 31;302(5646):875-8.

26.

Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients.

Woodward RS, Schnitzler MA, Baty J, Lowell JA, Lopez-Rocafort L, Haider S, Woodworth TG, Brennan DC.

Am J Transplant. 2003 May;3(5):590-8.

27.
28.

Cutaneous injection of human subjects with macrophage inflammatory protein-1 alpha induces significant recruitment of neutrophils and monocytes.

Lee SC, Brummet ME, Shahabuddin S, Woodworth TG, Georas SN, Leiferman KM, Gilman SC, Stellato C, Gladue RP, Schleimer RP, Beck LA.

J Immunol. 2000 Mar 15;164(6):3392-401.

30.

Interleukin-2 receptor-specific fusion toxin inhibits barotrauma-induced arterial atherosclerosis.

Miller DD, Bach RG, Tio FO, Bailey SR, Waters CA, Woodworth TG, Nichols JC, Paige SB, Farrar M.

Atherosclerosis. 1996 Sep 27;126(1):1-14.

PMID:
8879429
31.

Interleukin-2 diphtheria fusion protein (DAB486IL-2) in refractory rheumatoid arthritis. A double-blind, placebo-controlled trial with open-label extension.

Moreland LW, Sewell KL, Trentham DE, Bucy RP, Sullivan WF, Schrohenloher RE, Shmerling RH, Parker KC, Swartz WG, Woodworth TG, et al.

Arthritis Rheum. 1995 Sep;38(9):1177-86.

PMID:
7575710
32.

Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis.

Gottlieb SL, Gilleaudeau P, Johnson R, Estes L, Woodworth TG, Gottlieb AB, Krueger JG.

Nat Med. 1995 May;1(5):442-7.

PMID:
7585092
33.

Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies.

Platanias LC, Ratain MJ, O'Brien S, Larson RA, Vardiman JW, Shaw JP, Williams SF, Baron JM, Parker K, Woodworth TG.

Leuk Lymphoma. 1994 Jul;14(3-4):257-62.

PMID:
7950914
34.

Phase I trial of an interleukin-2 fusion toxin (DAB486IL-2) in hematologic malignancies: complete response in a patient with Hodgkin's disease refractory to chemotherapy.

Tepler I, Schwartz G, Parker K, Charette J, Kadin ME, Woodworth TG, Schnipper LE.

Cancer. 1994 Feb 15;73(4):1276-85.

PMID:
8313331
35.

Interleukin-2 receptor-directed therapies: antibody- or cytokine-based targeting molecules.

Strom TB, Kelley VR, Murphy JR, Nichols J, Woodworth TG.

Adv Nephrol Necker Hosp. 1994;23:347-56. Review. No abstract available.

PMID:
8154364
36.

DAB486IL-2 fusion toxin in refractory rheumatoid arthritis.

Sewell KL, Parker KC, Woodworth TG, Reuben J, Swartz W, Trentham DE.

Arthritis Rheum. 1993 Sep;36(9):1223-33.

PMID:
8216416
38.

Interleukin-2 receptor-directed therapies: antibody-or cytokine-based targeting molecules.

Strom TB, Kelley VR, Murphy JR, Nichols J, Woodworth TG.

Annu Rev Med. 1993;44:343-53. Review.

PMID:
8476255
39.

Recombinant fusion toxins--a new class of targeted biologic therapeutics.

Woodworth TG, Nichols JC.

Cancer Treat Res. 1993;68:145-60. Review.

PMID:
8105849
40.

Interleukin-2 receptor-directed immunosuppressive therapies: antibody- or cytokine-based targeting molecules.

Strom TB, Kelley VR, Woodworth TG, Murphy JR.

Immunol Rev. 1992 Oct;129:131-63. Review. No abstract available.

PMID:
1464418
41.

Severe glomerulonephritis with late emergence of classic Wegener's granulomatosis. Report of 4 cases and review of the literature.

Woodworth TG, Abuelo JG, Austin HA 3rd, Esparza A.

Medicine (Baltimore). 1987 May;66(3):181-91.

PMID:
3574116

Supplemental Content

Loading ...
Support Center